Scientific Due Diligence
for Biotech Investors. Delivered in Days.
Over half a dozen due diligence reports delivered for biotech investment decisions — from a researcher who has built the science, filed the patents, and published in Nature.
The Problem With Biotech Due Diligence
No Scientific Depth
Investment teams are strong on finance but can't evaluate whether the biology actually works
Deals Move Fast
Traditional scientific due diligence takes weeks — by which time the deal has closed or moved on
AI Isn't Enough
AI tools miss biotech-specific nuance, hallucinate claim dependencies, and can't interpret what the science means
What if you could get PhD-level scientific judgment at the speed the deal actually requires?
What We Do
IP Intelligence Services
Scientific Due Diligence
Rapid PhD-level scientific assessment for biotech investment decisions — technology feasibility, IP strength, and key risk factors in days, not weeks.
Patent Landscape Analysis
Structured patent landscape mapping with technology clustering, white space identification, and competitive intelligence — interpreted by a named inventor who understands the underlying science.
Prior Art Search & Patentability Assessment
Thorough prior art identification and claim-by-claim scientific analysis — grounded in the perspective of a named inventor who has been through the process.
IP Intelligence Monitoring
Continuous intelligence on patent filings and competitor activity in your technology area — interpreted by a scientist, not just a search algorithm.
Scientific Advisory & Strategy
Ongoing scientific advisory for investors and founders who need a trusted PhD-level voice to pressure-test claims, evaluate technology, and inform strategy.
The Scientist Behind the Analysis
Dr. Gregory Newkirk
Dr. Newkirk has delivered over half a dozen technical due diligence reports for biotech investment groups, evaluating technology feasibility, IP strength, and scientific risk across CRISPR, nanotechnology, and molecular biology. Before that, more than a decade at the bench — at BASF leading CRISPR programs, at Cibus building NGS pipelines, and as a doctoral researcher publishing in Nature Nanotechnology.
He is also a named inventor on U.S. Patent 11,186,845 B1 and a graduate of the Casimir Jones Life Sciences Patent Academy. That combination of hands-on science and IP training means every analysis reflects genuine understanding of both the biology and the claims.
Full Bio & CredentialsProcess
How It Works
Define
You share the technology, therapeutic area, or patent portfolio
Analyze
AI-accelerated search + PhD-level scientific interpretation
Deliver
Actionable intelligence report in days, not months
Newsletter
CRISPR Patent Intelligence — Weekly
Patent filings. Litigation updates. Licensing deals. Decoded by a molecular biologist.
Join biotech professionals staying ahead of the IP landscape. No spam, unsubscribe anytime.